20 January 2025 - Eli Lilly and Company today announced that the US FDA has granted breakthrough therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. 

Sofetabart mipitecan is a novel folate receptor alpha antibody-drug conjugate that uses proprietary linker technology and an exatecan payload.

Read Eli Lilly press release